



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ashkenazi, et al. Docket No.: 39780-1618P2C39
Serial No.: 09/904,992 Group Art Unit: 1636
Filing Date: July 12, 2001 Examiner: Leffers Jr., Gerald G.
For: **SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
ACIDS ENCODING THE SAME**

SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. §1.97

MS: Box DD

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

☐ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):

☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)

-- OR --

CERTIFICATE OF MAILING (37 CFR 1.10(a))

CERTIFICATE OF MAILING BY "EXPRESS MAIL" - Rule 10. I hereby certify that this correspondence is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" under 37 CFR 1.10 as **Express Mail No. EV3467280761** S addressed to: Mail Stop No-Fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: May 27, 2003

Cheryl Ann Rogers
Cheryl Ann Rogers

- ☐ (2) It is being filed within 3 months of entry of a national stage
-- OR --
☐ (3) It is being filed before the mail date of the first Office Action on the merits
-- OR --
☐ (4) It is being filed before the mailing of a first Office Action after the
filing of a request for continued examination under § 1.114.

☒ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:

☐ a certification as specified in §1.97(e) is provided below; **or**

☒ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:

A. a certification as specified in §1.97(e) is completed below; and

B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; **and**

C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

☒ *Fee Authorization.* The Commissioner is hereby authorized to charge the above-referenced fees of \$180.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No. 39780-1618P2C39).

Respectfully submitted,

Dated: May 27, 2003

By: 
Ginger R. Dreger, Reg. No. 33,055

HELLER EHRMAN WHITE & MCAULIFFE, LLP

Customer No. 34589

275 Middlefield Road

Menlo Park, CA 94025-3506

Tel: (650) 324-7000


Fax: (650) 324-0638



SHEET 1 OF 5

INFORMATION DISCLOSURE STATEMENT PTO-1449	ATTY. DOCKET NO. 39780-1618P2C39	SERIAL NO. 09/904,992
	APPLICANT Ashkenazi et al.	
	FILING DATE: 07/12/01	GROUP: 1636
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	Fong et al; "Composition comprising a PRO230, PRO216 or PRO302 polypeptide, agonist or antagonist for promoting or inhibiting angiogenesis and/or cardiovascularisation in mammals", P_AAF30502; WO200119987-A1, Pat 29 May, 2001, filed: November 29, 1999.	
	Fong et al; "A composition comprising PRO230, PRO216 or PRO302 polypeptides, agonists or antagonists useful for promotion or inhibition of cardiovascularisation, angiogenesis or endothelialisation in mammals", P_AAA13199; WO200015792-A2, Pat 20 July 2000, filed: September 13, 1999.	
	Chen, et al; "New isolated human genes and polypeptides used in, e.g. treatment of gastrointestinal ulceration", P_AAX52258; WO9914328-A2, Pat 25 June 1999, filed: September 16, 1998.	
	Fong et al; "Composition comprising human polypeptides with anti-angiogenic activity", P_AAX25445; WO9914234-A2; Pat 19 July 1999, filed: September 14, 1998.	
	Ashkenazi et al; "Sixty one nucleic acids encoding PRO polypeptides which are useful in the treatment of skin diseases, cancers and neurodegenerative diseases", P_AAF72416; WO200104311-A1, Pat 24 April 2001, Filed: Feb. 22, 2000.	
	Baker et al; "One hundred and eighty seven nucleic acids encoding PRO polypeptides, useful in diagnosis and treatment of cardiovascular, endothelial or angiogenic disorders in a mammal", P_ABL95586; WO200208284-A2, Pat 19 July 2002, Filing: July 9, 2001.	
	Baker et al; "One hundred and eighty seven nucleic acids encoding PRO polypeptides, useful in diagnosis and treatment of cardiovascular, endothelial or angiogenic disorders in a mammal", P_ABL88097; WO200200690-A2, Pat 16 May 2002, Filing: June 20, 2001.	
	Fong et al; "Promotion or inhibition of angiogenesis and cardiovascularization," AX098272; WO0119987-A11, Pat 2 Apr, 2001, Pub: Mar. 22, 2001.	
	Baker et al; "Composition and methods for the diagnosis and treatment of disorders involving angiogenesis" AX454466; WO0208284-A 51; Pat 6 July 2002, Pub: Jan 31, 2002.	
	Wood et al; "Secretory and transmembrane polypeptide and nucleic acid encoding the same" BD075577; JP2001516580-A 210, Pat 27 Aug. 2002, Oct 2, 2001.	
	Wood et al; "Secretory and transmembrane polypeptide and nucleic acid encoding the same" BD173394; JP2002238588-A 210, Pat 18 Feb. 2003.	
	Wood et al; "Secretory and transmembrane polypeptide and nucleic acid encoding the same" BD173075; JP2002238587-A 210, Pat 18 Feb. 2003.	
	Baker et al; "Composition and methods for the diagnosis and treatment of disorders involving angiogenesis" AX490944; WO0200690-A51; Pat 16 Aug. 2002.	
	Wood et al; "Secretory and transmembrane polypeptide and nucleic acid encoding the same" BD172756; JP2002238586-A 210; Pat 18 Feb. 2003.	
EXAMINER		DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



SHEET 2 OF 5

INFORMATION DISCLOSURE STATEMENT PTO-1449	ATTY. DOCKET NO. 39780-1618P2C39	SERIAL NO. 09/904,995
	APPLICANT Ashkenazi et al.	
	FILING DATE: 07/12/01	GROUP: 1636
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	Wood et al; "Secretory and transmembrane polypeptide and nucleic acid encoding the same" BD172437; JP2002223786-A 210; Pat 18 Feb, 2003.	
	Wood et al; "Secretory and transmembrane polypeptide and nucleic acid encoding the same" BD175428; JP2002253280-A 210; Pat 18 Mar, 2003.	
	Miano et al. "New retinoid-inducible serine carboxypeptidase proteins and nucleic acids, useful for detecting or treating vascular diseases, e.g. vascular hyperplasia, atherosclerosis, asthma, glomerulonephritis, hypertension" P_ABV72656; WO200268599-A2, Pat 29 Nov, 2002.	
	White et al; "Identifying a gene involved in disease for treating hypoxia-regulated conditions, comprises comparing the transcriptome/ proteome of two cell types under different conditions and identifying a differentially regulated gene" P_ABV77921; WO200246465-A2, Pat 12 Nov, 2002.	
	Cho et al; "Cloning of novel serine carboxypeptidase precursor" Direct submission to Microbiology, Kyung Hee University, Hoeki 1, Seoul, Korea; AF282618; Submitted 26 June, 2000, Priority 27 Sep, 2000.	
	Chen et al; "Cloning of a novel retinoid-inducible serine carboxypeptidase from vascular smooth muscle cells" NM_021626; J. Biol. Chem. 276 (36), 34175-181 (2001).	
	Ota et al; "Primer sets for synthesizing polynucleotides, particularly the 5602 full-length cDNAs defined in the specification, and for the detection and/or diagnosis of the abnormality of the proteins encoded by the full-length cDNAs" P_AAH15579; EP1074617-A2, Pat 26 June, 2001.	
	Schlegel et al; "Novel isolated nucleic acid molecule associated with cancerous state of prostate cells and correlating with presence of prostate cancer, useful for detecting presence of prostate cancer, stage of prostate cancer" P_ABV28721; WO200160860-A2; Pat 16 Sep, 2002.	
	Isogai et al; Direct submission to Helix Research Institute, Genomics Laboratory, 1532-3 Yana, Kisarazu, Chiba 292-0812, Japan; AK027373; submitted 10 May, 2001.	
	Ota et al; "Primer for synthesizing full-length cDNA and use thereof"; BD157571; JP 2002191363-A12414; Pat 17 Jan, 2003.	
	Schlegel et al; "New isolated nucleic acid for diagnosing and treating cervical cancer and for assessing and detecting compounds for treating the cancer"; P_AAH72787; WO200142467-A2; Pat 19 Sep, 2001.	
	Schlegel et al; "Genes, compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer"; AX188369; WO0142467-A 4064; Pat 6 Aug, 2001.	
	Kato et al; "Human proteins with hydrophobic domains and the nucleic acids encoding them, useful for preventing diagnosing and treating e.g. cancer, Alzheimer's and inflammation"; P_AAD12590; WO200149728-A2; Pat 25 Sep, 2001.	
	Kato et al; "Human proteins having hydrophobic domains and DNAs encoding these proteins"; AX191563; WO0149728-A85; Pat 15 Aug, 2001.	
EXAMINER		DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




SHEET 3 OF 5

RECEIVED
JUN 02 2003
TECH CENTER 1600/2800

INFORMATION DISCLOSURE STATEMENT PTO-1449	ATTY. DOCKET NO. 39780-1618P2C39	SERIAL NO. 09/904,992
	APPLICANT Ashkenazi et al.	
	FILING DATE: 07/12/01	GROUP: 1636
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	Liu et al; Direct submission to Molecular Medical Center for Cardiovascular Disease, Cardiovascular Institute, 167, Bei Li Shi Lu, Beijing 100037, P.R. China; AF113214; submitted 15 Dec, 1998.	
	Shimkets et al; "Novel nucleic acids and peptides derived from open reading frame X, useful for treating e.g. cancers, proliferative disorders, neurodegenerative disorders and cardiovascular disease," P_AAC75884; WO200058473-A2, Pat 8 Feb, 2001.	
	Robison, K. E.; "New polynucleotides encoding protease homologs of the G-protein-coupled protease family, useful in identifying agonists and antagonists for diagnosis and treatment of protease mediated disorders," P_ABK30363; US6331427-B1, Pat 23 Apr, 2002.	
	Ford et al; "Novel bone-marrow-expressed polynucleotides and polypeptides, useful for treating e.g. cancer and immune deficiency disorders," P_AAH89926; WO200153453-A2; Pat 1 Oct, 2001.	
	Kato et al; "Human proteins having hydrophobic domains and DNAs encoding these proteins," AX191553; WO0149728-A75; Pat 15 Aug, 2001.	
	Fong et al; "Composition comprising a PRO230, PRO216 or PRO302 polypeptide, agonist or antagonist for promoting or inhibiting angiogenesis and/or cardiovascularisation in mammals", P_AAB20341; WO200119987-A1, Pat 29 May, 2001, filed: November 29, 1999; Publication date: 22 March 2001.	
	Ota et al; "Primer sets for synthesizing polynucleotides, particularly the 5602 full-length cDNAs defined in the specification, and for the detection and/or diagnosis of the abnormality of the proteins encoded by the full-length cDNAs" P_AAB93913; EP1074617-A2; Pat 26 June, 2001; Publication date: 07 February 2001.	
	Kato et al; "Human proteins with hydrophobic domains and the nucleic acids encoding them, useful for preventing diagnosing and treating e.g. cancer, Alzheimer's and inflammation"; P_AAE06595; WO200149728-A2; Pat 25 Sep, 2001; Publication date: 12 July 2001.	
	Fong et al; "Composition comprising a PRO230, PRO216 or PRO302 polypeptides, agonists or antagonists useful for promotion or inhibition of cardiovascularisation, angiogenesis or endothelialisation in mammals", P_AAY88378; WO200015792-A2, filed: September 13, 1999; Publication date: 23 March 2000.	
	Chen, et al. "New isolated human genes and polypeptides used in, e.g. treatment of gastrointestinal ulceration", P_AAY13387; WO9914328-A2, Pat 25 Jun, 1999, filed: September 16, 1998; Publication date: 25 March 1999.	
	Fong et al, "Composition containing human polypeptides with anti-angiogenic activity", P_AAY05768; WO9914234-A2; filed: September 14, 1998; Publication date: 25 March 1999.	
	Kato et al; unnamed protein product; CAC51169.1; WO0149728-A85; 12 Jul, 2001; Publication date: .	
	Cho et al; Direct submission to Microbiology, Kyung Hee University, Hoeki 1, Seoul, Korea; AAG16692.1; Submitted 26 June, 2000.	
	Isogai et al; Direct submission to Helix Research Institute, Genomics Laboratory, 1532-3 Yana, Kisarazu, Chiba 292-0812, Japan; BAB55069.1; submitted 10 May, 2001.	
EXAMINER		DATE CONSIDERED

EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant



INFORMATION DISCLOSURE STATEMENT PTO-1449	ATTY. DOCKET NO. 39780-1618P2C39	SERIAL NO. 09/904,992
	APPLICANT Ashkenazi et al.	
	FILING DATE: 07/12/01	GROUP: 1636
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	Cho et al; "Cloning of novel serine carboxypeptidase precursor" Direct submission to Microbiology, Kyung Hee University, Hoeki 1, Seoul, Korea; RISC_HUMAN; Submitted 26 June, 2000. Komatsoulis et al; "Isolated nucleic acid molecules encoding a human secreted protein is used in preventing, treating or ameliorating a medical condition," P_AAU96225; WO200224721-A1; Filing: 9 Jan, 2001; Publication date: 28 March 2002.	
	Shimkets et al; "Novel nucleic acids and peptides derived from open reading frame X, useful for treating e.g. cancers, proliferative disorders, neurodegenerative disorders and cardiovascular disease," P_AAB41675; WO200058473-A2, Filing: 31 March 1999; Publication date: 05 October 2000. Liu et al; Direct submission to Molecular Medical Center for Cardiovascular Disease, Cardiovascular Institute, CAMS AND PUMC; 167, Bei Li Shi Lu, Beijing 100037, P.R. China; AAG39285.1; Accession No: AF113214; submitted 15 December 1998.	
	Chen et al; "Cloning of a novel retinoid-inducible serine carboxypeptidase from vascular smooth muscle cells," J. Biol. Chem. 276 (36), 34175-34181 (2001); NP_067639. Baker et al; "One hundred and eighty seven nucleic acids encoding PRO polypeptides, useful in diagnosis and treatment of cardiovascular, endothelial or angiogenic disorders in a mammal", P_ABB84842; WO200200690-A2, Pat 19 Jul, 2002, Filing: July 9, 2001; Publication Date: January 3, 2002.	
	Baker et al; "One hundred and eighty seven nucleic acids encoding PRO polypeptides, useful in diagnosis and treatment of cardiovascular, endothelial or angiogenic disorders in a mammal", P_ABB95448; WO200208284-A2, Pat 19 Jul, 2002, Filing: July 9, 2001; Publication Date: January 31, 2002. White et al; "Identifying a gene involved in disease for treating hypoxia-regulated conditions, comprises comparing the transcriptome/ proteome of two cell types under different conditions and identifying a differentially regulated gene" P_ABP65102; WO200246465-A2; Publication Date: 13 June 2002; Pat 12 Nov, 2002.	
	Miano et al; "New retinoid-inducible serine carboxypeptidase proteins and nucleic acids, useful for detecting or treating vascular diseases, e.g. vascular hyperplasia, atherosclerosis, asthma, glomerulonephritis, hypertension" P_ABB99215; WO200268599-A2, Publication date: 06 September 2002 Pat 29 Nov, 2002. Ashkenazi et al; "Sixty one nucleic acids encoding PRO polypeptides which are useful in the treatment of skin diseases, cancers and neurodegenerative diseases", P_AAB80255; WO200104311-A1 Pat 24 Apr, 2001, Filed: February 22, 2000, Publication date: 18 January 2001.	
EXAMINER	DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

